CG Oncology, Inc.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing bladder cancer therapeutics designed to preserve the bladder rather than require surgical removal. The company's pipeline centers on cretostimogene, an oncolytic immunotherapy candidate being evaluated across multiple indications and combination regimens. Its lead program, BOND-003, is in Phase 3 clinical development for high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. Additional Phase 2 and Phase 3 candidates include CORE-001 and CORE-002, which combine cretostimogene with checkpoint inhibitors pembrolizumab and nivolumab respectively, as well as PIVOT-006 for intermediate-risk NMIBC and CORE-008 for high-risk NMIBC in both BCG-exposed and BCG-naïve patient populations.

The company operates as a clinical-stage entity with no approved products or meaningful revenue streams. CG Oncology was incorporated in Delaware and is headquartered in Irvine, California. Originally founded in 2010 as Cold Genesys, Inc., the company rebranded as CG Oncology in June 2020 to reflect its strategic focus on oncology. The company is publicly listed on Nasdaq with a market capitalization of approximately $4.9 billion as of the last available data.